<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01708187</url>
  </required_header>
  <id_info>
    <org_study_id>OH1-12-00396</org_study_id>
    <nct_id>NCT01708187</nct_id>
  </id_info>
  <brief_title>The Role of C-HAM in the Surgical Repair of Peroneal Tendons: An Infrared Thermography Model</brief_title>
  <acronym>Amniox</acronym>
  <official_title>The Role of Cryopreserved Human Amniotic Membrane in the Surgical Repair of Peroneal Tendons: An Infrared Thermography Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orthopedic Foot and Ankle Center, Ohio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orthopedic Foot and Ankle Center, Ohio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peroneal tendon tears are a common etiology encountered by foot and ankle surgeons. Like all
      flexor tendon repairs adhesions are one of the more common challenges after surgery. Peroneal
      tendon gliding is key to their function as effective plantar flexors and evertors of the
      hindfoot. Scarring and adhesion correlate directly with the amount of inflammatory reaction
      at the wound site (Adzick 1994). Our goal is to have a surgical technique that allows for
      standard suture repair of the tendon yet allows for smooth gliding of the tendon with minimal
      adhesions. A prospective review on the surgical repair of the peroneal tendons utilizing
      Clarix™1k (Amniox Medical, Marietta, GA), cryopreserved Human Amniotic Membrane (C-HAM) graft
      will be performed. The investigators hypothesize that the use of cryopreserved Human Amniotic
      Membrane in conjunction with a peroneal tendon repair will decrease that amount of
      inflammation, overall recovery time of surgically repaired peroneal tendon tears, and
      adhesions.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol halted due to less than anticipated recruitment.
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ankle Pain, Inflammation, Function &amp; Activity Limitation From Baseline to 12 Months</measure>
    <time_frame>Baseline,12 months</time_frame>
    <description>Ankle pain measured via visual analog scale (VAS), function measured by American Orthopaedic Foot and Ankle Society (AOFAS) ankle hindfoot scale and Foot Function Index (FFI), activity limitation measured by AOFAS scale. Images taken via thermal camera to measure inflammation were not interpretable.
VAS pain scale: 0-100, with a lower number representing a better score FFI scale: 0-100, with a lower number representing a better score AOFAS scale: 0-100, with a higher number representing a better score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Tendon Tears</condition>
  <arm_group>
    <arm_group_label>Clarix™1k graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm without Clarix™1k graft</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clarix™1k graft</intervention_name>
    <description>Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.</description>
    <arm_group_label>Clarix™1k graft</arm_group_label>
    <other_name>cryopreserved Human Amniotic Membrane (C-HAM) graft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients requiring surgical repair of the peroneal tendon

          2. Patients who voluntarily consent to research participation

          3. Patients over the age of 18

        Exclusion Criteria:

          1. Patients who display a high surgical risk as determined by the investigative surgeon

          2. Previous surgical repair of the peroneal tendon less than 2 years prior to surgery

          3. Peroneus brevis tears in zone 3 or 4 that may hinder recovery in the investigator's
             opinion

          4. Patients with allergy or history of drug reactions to Ciprofloxacin or Amphotericin B

          5. Patients who are pregnant or breast feeding.

          6. Patients who have had a clinically diagnosed autoimmune disease

          7. Patients who are unwilling to restrict pre and postoperative anti-inflammatories with
             the exception of ecotrin 325 mg QD for DVT prophylaxis during the postoperative
             immobilization period

          8. Patients with an active infection

          9. Patients who have a medical history that would likely make the patient an unreliable
             research participant

         10. Patients requiring surgical repair of the peroneus longus tendon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory C Berlet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedic Foot and Ankle Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopedic Foot and Ankle Center</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2012</study_first_submitted>
  <study_first_submitted_qc>October 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <results_first_submitted>April 13, 2016</results_first_submitted>
  <results_first_submitted_qc>April 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2016</results_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Orthopedic Foot and Ankle Center, Ohio</investigator_affiliation>
    <investigator_full_name>Greg Berlet</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Peroneal tendon</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clarix™1k Graft</title>
          <description>Group 1 received standard peroneal repair surgery with the addition of the Clarix™1k tissue.</description>
        </group>
        <group group_id="P2">
          <title>Control Arm Without Clarix™1k Graft</title>
          <description>Group 2 received standard peroneal repair surgery without the use of the Clarix™1k tissue.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clarix™1k Graft</title>
          <description>Group 1 received standard peroneal repair surgery with the addition of the Clarix™1k tissue.</description>
        </group>
        <group group_id="B2">
          <title>Control Arm Without Clarix™1k Graft</title>
          <description>Group 2 received standard peroneal repair surgery without the use of the Clarix™1k tissue.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Ankle Pain, Inflammation, Function &amp; Activity Limitation From Baseline to 12 Months</title>
        <description>Ankle pain measured via visual analog scale (VAS), function measured by American Orthopaedic Foot and Ankle Society (AOFAS) ankle hindfoot scale and Foot Function Index (FFI), activity limitation measured by AOFAS scale. Images taken via thermal camera to measure inflammation were not interpretable.
VAS pain scale: 0-100, with a lower number representing a better score FFI scale: 0-100, with a lower number representing a better score AOFAS scale: 0-100, with a higher number representing a better score</description>
        <time_frame>Baseline,12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clarix™1k Graft</title>
            <description>Group 1 received standard peroneal repair surgery with the addition of the Clarix™1k tissue.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm Without Clarix™1k Graft</title>
            <description>Group 2 received standard peroneal repair surgery without the use of the Clarix™1k tissue.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Pain, Inflammation, Function &amp; Activity Limitation From Baseline to 12 Months</title>
          <description>Ankle pain measured via visual analog scale (VAS), function measured by American Orthopaedic Foot and Ankle Society (AOFAS) ankle hindfoot scale and Foot Function Index (FFI), activity limitation measured by AOFAS scale. Images taken via thermal camera to measure inflammation were not interpretable.
VAS pain scale: 0-100, with a lower number representing a better score FFI scale: 0-100, with a lower number representing a better score AOFAS scale: 0-100, with a higher number representing a better score</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS pain at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS pain at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in VAS pain from Baseline to 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFI at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFI at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FFI from Baseline to 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AOFAS at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AOFAS at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in AOFAS from Baseline to 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clarix™1k Graft</title>
          <description>Group 1 received standard peroneal repair surgery with the addition of the Clarix™1k tissue.</description>
        </group>
        <group group_id="E2">
          <title>Control Arm Without Clarix™1k Graft</title>
          <description>Group 2 received standard peroneal repair surgery without the use of the Clarix™1k tissue.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to only one subject completing the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gregory Berlet, MD</name_or_title>
      <organization>Orthopedic Foot and Ankle Center</organization>
      <phone>614-895-8747</phone>
      <email>ofacresearch@orthofootankle.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

